WO2009117661A3 - Carrier neutralization assay - Google Patents
Carrier neutralization assay Download PDFInfo
- Publication number
- WO2009117661A3 WO2009117661A3 PCT/US2009/037811 US2009037811W WO2009117661A3 WO 2009117661 A3 WO2009117661 A3 WO 2009117661A3 US 2009037811 W US2009037811 W US 2009037811W WO 2009117661 A3 WO2009117661 A3 WO 2009117661A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carrier
- bound
- hiv
- target cell
- assay
- Prior art date
Links
- 238000003556 assay Methods 0.000 title abstract 4
- 238000006386 neutralization reaction Methods 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 230000003472 neutralizing effect Effects 0.000 abstract 2
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 239000000232 Lipid Bilayer Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70514—CD4
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
A unique assay is disclosed for evaluating neutralization of HIV -I virus. The assay uses a carrier cell that contains a lipid bilayer with lipids that allows binding of HIV-I but that cannot be infected by virus. The carrier-bound HIV-I still retains the ability to move from the carrier to a target cell when it is co-cultured with the target cell. In the assay, the carrier-bound HIV-1 is exposed to candidate neutralizing antibodies, and non-bound antibodies are washed away. The carrier-bound HlV-l containing bound antibody is then evaluated for the ability to infect any relevant target cell (such as a CD4-positive lymphocyte), and the degree of infectivity of the target cell will reflect the relative neutralizing activity (if any) of the antibody that was used to coat the carrier-bound HIV-1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7062008P | 2008-03-20 | 2008-03-20 | |
US61/070,620 | 2008-03-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009117661A2 WO2009117661A2 (en) | 2009-09-24 |
WO2009117661A3 true WO2009117661A3 (en) | 2009-12-30 |
Family
ID=41091556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/037811 WO2009117661A2 (en) | 2008-03-20 | 2009-03-20 | Carrier neutralization assay |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009117661A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2492279A1 (en) | 2011-02-25 | 2012-08-29 | Laboratorios Del. Dr. Esteve, S.A. | Rapid immunogen selection method using lentiviral display |
EP2698377A1 (en) | 2012-08-17 | 2014-02-19 | Laboratorios Del. Dr. Esteve, S.A. | Enhanced rapid immunogen selection method for HIV gp120 variants |
CN115753652A (en) * | 2022-11-03 | 2023-03-07 | 江苏力博医药生物技术股份有限公司 | Method for quantitatively detecting RhD antigen by using erythrocyte endogenous peroxidase |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817767A (en) * | 1993-02-24 | 1998-10-06 | Progenics Pharmaceuticals, Inc. | Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same |
US20060194247A1 (en) * | 2003-02-06 | 2006-08-31 | Matti Sallberg | Glycosylated specificity exchangers |
US20070264265A1 (en) * | 2006-05-15 | 2007-11-15 | Immunomedics, Inc. | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments |
-
2009
- 2009-03-20 WO PCT/US2009/037811 patent/WO2009117661A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817767A (en) * | 1993-02-24 | 1998-10-06 | Progenics Pharmaceuticals, Inc. | Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same |
US20060194247A1 (en) * | 2003-02-06 | 2006-08-31 | Matti Sallberg | Glycosylated specificity exchangers |
US20070264265A1 (en) * | 2006-05-15 | 2007-11-15 | Immunomedics, Inc. | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments |
Non-Patent Citations (6)
Title |
---|
ALVING ET AL.: "HIV-1, lipid rafts, and antibodies to liposomes: implications for anti-viral- neutralizing antibodies (Review).", MOLECULAR MEMBRANE BIOLOGY, vol. 23, no. 6, November 2006 (2006-11-01), pages 453 - 465, XP008080215 * |
HORAKOVA ET AL.: "Complement Mediates the Binding of HIV to Erythrocytes.", THE JOURNAL OF IMMUNOLOGY, vol. 173, 2004, pages 4236 - 4241 * |
LACHGAR ET AL.: "Binding of HIV-I to RBCs involves the Duffy Antigen Receptors for Chemokines (DARC).", BIOMED & PHARMACOTHER, vol. 52, 1998, pages 436 - 439 * |
MELHOP ET AL.: "Protective immune responses against West Nile virus are primed by distinct complement activation pathways.", JEM, vol. 203, no. 5, 15 May 2006 (2006-05-15), pages 1371 - 1381 * |
OLLINGER ET AL.: "CD4-Negative Cells Bind Human Immunodeficiency Virus Type 1 and Efficiently Transfer Virus to T Cells.", JOURNAL OF VIROLOGY, vol. 74, no. 18, September 2000 (2000-09-01), pages 8550 - 8557 * |
TANTENO ET AL.: "Human immunodeficiency virus can infect CD4-negative human fibroblastoid cells.", PROC. NAD. ACAD. SCI. USA, vol. 86, June 1989 (1989-06-01), pages 4287 - 4290 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009117661A2 (en) | 2009-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201856T1 (en) | Antibodies that bind to human programmed death ligand 1 (pd-l1) | |
WO2013070776A8 (en) | Neutralizing gp41 antibodies and their use | |
EA201400108A1 (en) | OPTIONS OF POLYPEPTIDES AND THEIR APPLICATIONS | |
CR20120042A (en) | DIRECTED IMMUNOCATE PLAYERS | |
WO2010010466A3 (en) | Neutralizing anti-influenza a virus antibodies and uses thereof | |
ATE549624T1 (en) | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF FLU | |
WO2011100708A3 (en) | Assay card for sample acquisition, treatment and reaction | |
JP2012105660A5 (en) | ||
WO2007047579A3 (en) | A novel therapeutic target for protozoal diseases | |
WO2013165972A3 (en) | Anti-hepatitis b virus antibodies and use thereof | |
BR112013016495A2 (en) | A monoclonal antibody which recognizes human papilloma virus (HPV) L2 protein, and a HPV neutralization antibody value measuring method which uses it | |
WO2009031045A3 (en) | Anti-chikungunya monoclonal antibodies and uses thereof | |
MX2010004251A (en) | Anti-bst2 antibody. | |
WO2011092593A3 (en) | Hiv-1 neutralizing antibodies and uses thereof | |
CY1121856T1 (en) | JCV NEUTRALIZING ANTIBODIES | |
EA201400447A1 (en) | ANTIBODIES TO CD1d | |
EP2577307A4 (en) | A diagnostic assay | |
WO2013142300A3 (en) | Jcv neutralizing antibodies | |
WO2015196192A3 (en) | Methods and compositions relating to dengue virus | |
WO2009117661A3 (en) | Carrier neutralization assay | |
BR112014023063A2 (en) | antibodies that neutralize rsv, mpv and pvm and their uses | |
WO2012103337A3 (en) | Assays and methods to sequence microbes directly from immune complexes | |
EA201370030A1 (en) | BIFUNCTIONAL QUANTITATIVE IN VITRO ANALYSIS OF BINDING TARGETS FOR DETECTING NEUTRALIZING ANTIBODIES TO TARGET ANTIBODIES | |
WO2011146120A3 (en) | Assay for identifying antigens that activate b cell receptors comprising neutralizing antibodies | |
Traoré et al. | Seroreactivity of the severe acute respiratory syndrome coronavirus 2 recombinant S protein, receptor-binding domain, and its receptor-binding motif in COVID-19 patients and their cross-reactivity with pre-COVID-19 samples from malaria-endemic areas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09721407 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09721407 Country of ref document: EP Kind code of ref document: A2 |